Abcellera Biologics Inc ABCL

$11.07 -0.05 (-0.45%)

Valuation

Market cap
3,752,841,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
1,685,933
Avg volume
4,308,192
Day's range
$10.81 – $11.40
Shares out
326,618,000
Stochastic %K
16%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

maestrodarkhorse Nov 17, 7:16 PM
$ABCL Execs keep buying, the CFO bought shares in the open market.. I have a feeling expedited FDA approval is coming.
2 replies
maestrodarkhorse Nov 17, 7:13 PM
$ABCL Love these emails! Andrew Booth, CFO of $ABCL , is loading up at ~$11. +8,600 shares for Andrew. No buys like insider buys after a 300% run.
0 replies
flymetothemoon2 Nov 17, 7:08 PM
$ABCL @erpy
0 replies
flymetothemoon2 Nov 17, 7:00 PM 0 replies
Buying_Low_Selling_High Nov 17, 6:59 PM
$ABCL Selling now is a mistake.
0 replies
JohnnyBoy272 Nov 17, 6:55 PM
$ABCL I think there will come a time when Peter Thiel joins AbCellera again. I believe Carl would absolutely love to have him back. Thiel left in 2024, shortly after AbCellera announced its transition from an antibody discovery and partnership company into a clinical-stage biotech. That’s a massive strategic shift, and I can understand why the increased risk might not have been attractive at that stage. But look where we are now. The VMS results have been very encouraging, and AbCellera has come a long way since 2024. The company is starting to demonstrate what its internally developed pipeline could become. From my understanding, Thiel may still hold shares, although I haven’t been able to independently verify his current position. I wouldn’t be surprised if we saw him become involved again sometime in 2027. Just a thought, but I think the story between Thiel and AbCellera might not be over yet.
1 replies
flymetothemoon2 Nov 17, 5:40 PM
$ABCL ABcellera 🔥 🔥!!!
0 replies
maestrodarkhorse Nov 17, 5:03 PM
$ABCL Notably 13F filings involving AbCellera $ABCL Shares Owned - Increase Q/Q Marshall Wace LLP: ~9.0M / +7,056,082 BlackRock, Inc. ~5.66–5.7M / +1.855,328 Arrowstreet Capital ~2M / +973,741 Jane Street Group~1.5M / +1,317,860 American Century ~1.3M / + 1,187,115 Interesting to note, American Century owned 1.3m ABCL shares in 2023. Sold 99% of their holdings. Bought that share count back in Q3 2026. Patience pays..
0 replies